Geriatric functional的問題，透過圖書和論文來找解法和答案更準確安心。 我們查出實價登入價格、格局平面圖和買賣資訊

功能性泌尿學

為了解決Geriatric functional的問題，作者郭漢崇等 這樣論述：

　　《功能性泌尿學》一書，從解剖學、神經學、生理學、症狀評估、尿路動力學檢查、膀胱過動症，談到神經性膀胱、各式排尿障礙、兒童的排尿障礙、年老者排尿問題、前列腺肥大、女性膀胱出口阻塞、間質性膀胱炎、小兒夜尿症、婦女尿失禁、骨盆底脫垂及重建以及功能障礙型排尿，一直到各種下尿路功能障礙的治療以及新發展。這本書涵概的內容可謂相當完整，可以讓一位年輕的醫師，由淺入深，了解功能性泌尿學的奧秘。－－郭漢崇／花蓮慈濟醫院泌尿部主任

Retinal Degenerative Diseases: Mechanisms and Experimental Therapy

為了解決Geriatric functional的問題，作者Ash, John (EDT)/ Anderson, Robert (EDT)/ Lavail, Matthew (EDT)/ 這樣論述：

The blinding diseases of inherited retinal degenerations have no treatments, and age-related macular degeneration has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 70. The RD Symposium will focus on the exciting new developments aimed at un

derstanding these diseases and providing therapies for them. Since most major scientists in the field of retinal degenerations attend the biennial RD Symposia, they are known by most as the "best" and "most important" meetings in the field. The volume will present representative state-of-the-art res

earch in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; candidate genes, cloning, mapping and other aspects of molecular genetics; and developing potential therapeutic measures such as gen

e therapy and neuroprotective agents for potential pharmaceutical therapy. While advances in these areas of retinal degenerations will be described, there will be many new topics that either were in their infancy or did not exist at the time of the last RD Symposium, RD2014. These include the role o

f inflammation and immunity, as well as other basic mechanisms, in age-related macular degeneration, several new aspects of gene therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as t

o provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and excitin

g initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS.Many of the successes recently reported in these areas of ret

inal degeneration sprang from collaborations established at previous RD Symposia, and many of those will be reported at the RD2018 meeting and included in the proposed volume. We anticipate the excitement of those working in the field and those afflicted with retinal degenerations will be reflected

in the volume. John D. Ash, Ph.D., Francis M. Bullard Eminent Scholar Chair in Ophthalmological Sciences, Department of Ophthalmology, College of Medicine at the University of Florida. Dr. Ash received his Ph.D. from the Ohio State University Biochemistry Program in 1994, and completed postdoctora

l training in the Cell Biology Department at Baylor College of Medicine, in Houston, Texas, and began his faculty career at the University of Oklahoma Health Sciences Center, Oklahoma. Dr. Ash is also a Visiting Professor at the Dalian Medical University, Dalian China. Dr. Ash has written and publis

hed 60 manuscripts including research articles, book chapters and invited reviews, and has edited four books. He is currently an Executive editor for Experimental Eye research and a Scientific Review Editor for Molecular Vision. Dr. Ash is an active reviewer for these journals as well as Investigati

ve Ophthalmology & Visual Science. In 2009, Dr. Ash received a research award from Hope for Vision, and in 2010 he received a Lew R. Wasserman Merit award from Research to Prevent Blindness, Inc. Dr. Ash has received grants from the National Institutes of Health, the Foundation Fighting Blindness, R

esearch to Prevent Blindness, Inc., Hope for Vision, and the American Diabetes Association. Dr. Ash has served on the Program and Advocacy committees of the Association for Research in Vision and Ophthalmology. Dr. Ash has served on the scientific review panel for Fight For Sight (2005-2008) and is

currently serving on the Scientific Advisory Board of the Foundation Fighting Blindness (Columbia, MD) where he chairs the review committee on Novel Medical Therapies Program. He also serves on the scientific review panel for the Macular Degeneration program of the BrightFocus Foundation (formerly t

he American Health Assistance Foundation, Clarksburg, MD).Robert Eugene Anderson, MD, Ph.D., is George Lynn Cross Research Professor, Dean A. McGee Professor of Ophthalmology, Professor of Cell Biology, and Adjunct Professor of Geriatric Medicine at The University of Oklahoma Health Sciences Cente

r in Oklahoma City, Oklahoma. He is also Director of Research at the Dean A. McGee Eye Institute. He received his Ph.D. in Biochemistry (1968) from Texas A&M University and his MD from Baylor College of Medicine in 1975. In 1968, he was a postdoctoral fellow at Oak Ridge Associated Universities. At

Baylor, he was appointed Assistant Professor in 1969, Associate Professor in 1976, and Professor in 1981. He joined the faculty of the University of Oklahoma Health Sciences Center in January of 1995. Dr. Anderson served as director of the Oklahoma Center for Neuroscience (1995-1999) and chairman of

the Department of Cell Biology (1998-2007). He has received several honorary appointments including Visiting Professor, West China School of Medicine, Sichuan University, Chengdu, China; Honorary Professorship, Xi’an Jiaotong University, Xi’an, China; and Honorary Professor of Sichuan Medical Scien

ce Academy, Sichuan Provincial People’s Hospital, Sichuan, China. Dr. Anderson has received the Sam and Bertha Brochstein Award for Outstanding Achievement in Retina Research from the Retina Research Foundation (1980), and the Dolly Green Award (1982) and two Senior Scientific Investigator Awards (1

990 and 1997) from Research to Prevent Blindness, Inc. He received an Award for Outstanding Contributions to Vision Research from the Alcon Research Institute (1985), and the Marjorie Margolin Prize (1994). He has served on the editorial boards of Investigative Ophthalmology and Visual Science, Jour

nal of Neuroscience Research, Neurochemistry International, Current Eye Research, and Experimental Eye Research. Dr. Anderson has published extensively in the areas of lipid metabolism in the retina and biochemistry of retinal degenerations. He has edited 18 books, 17 on retinal degenerations and on

e on the biochemistry of the eye. Dr. Anderson has received grants from the National Institutes of Health, The Retina Research Foundation, the Foundation Fighting Blindness, and Research to Prevent Blindness, Inc. He has been an active participant in the program committees of the Association for Res

earch in Vision and Ophthalmology (ARVO) and was a trustee representing the Biochemistry and Molecular Biology section. He was named a Gold Fellow by ARVO in 2009 and received the Proctor Medal from ARVO in 2011. He received the Llura Liggett Gund Lifetime Achievement Award from the Foundation Fight

ing Blindness in June 2011. In 2012, he received the Paul A. Kayser International Award, Retina Research Foundation. He received a Special Recognition Award from the ARVO Foundation in 2016 and was named a Fellow (Inaugural class of 12) of the International Society for the Study of Fatty Acids and L

ipids (ISSFAL). In 2016, the Dean McGee Eye Institute established the Robert E. Anderson Endowed Lectureship in his honor. He has served on the Vision Research Program Committee and Board of Scientific Counselors of the National Eye Institute and the Board of the Basic and Clinical Science Series of

The American Academy of Ophthalmology. Dr. Anderson is a past Councilor, Treasurer, and President of the International Society for Eye Research.Matthew M. LaVail, Ph.D., is Professor Emeritus of Anatomy and Ophthalmology at the University of California, San Francisco School of Medicine. He received

his Ph.D. degree in Anatomy (1969) from the University of Texas Medical Branch in Galveston and was subsequently a postdoctoral fellow at Harvard Medical School. Dr. LaVail was appointed Assistant Professor of Neurology-Neuropathology at Harvard Medical School in 1973. In 1976, he moved to UCSF, wh

ere he was appointed Associate Professor of Anatomy. He was appointed to his current position in 1982, and in 1988, he also became Director of the Retinitis Pigmentosa Research Center at UCSF, later named the Kearn Family Center for the Study of Retinal Degeneration. Dr. LaVail has published extensi

vely in the research areas of photoreceptor-retinal pigment epithelial cell interactions, retinal development, circadian events in the retina, genetics of pigmentation and ocular abnormalities, inherited retinal degenerations, light-induced retinal degeneration, and neuroprotective and gene therapy

for retinal degenerative diseases. He has identified several naturally occurring murine models of human retinal degenerations and has developed transgenic mouse and rat models of others. He is the author of more than 190 research publications and has co-edited 17 books on inherited and environmental

ly induced retinal degenerations. Dr. LaVail has received the Fight for Sight Citation (1976); the Sundial Award from the Retina Foundation (1976); the Friedenwald Award from the Association for Research in Vision and Ophthalmology (ARVO, 1981); two Senior Scientific Investigators Awards from Resear

ch to Prevent Blindness (1988 and 1998); a MERIT Award from the National Eye Institute (1989); an Award for Outstanding Contributions to Vision Research from the Alcon Research Institute (1990); the Award of Merit from the Retina Research Foundation (1990); the first John A. Moran Prize for Vision R

esearch from the University of Utah (1997); the first Trustee Award from The Foundation Fighting Blindness (1998); the fourth Llura Liggett Gund Award from the Foundation Fighting Blindness (2007); and he has received the Distinguished Alumnus Award from both his university (University of North Texa

s) and his graduate school (University of Texas Medical Branch). He has served on the editorial boards of Investigative Ophthalmology and Visual Science and Experimental Eye Research. Dr. LaVail has been an active participant in the program committee of ARVO and has served as a Trustee (Retinal Cell

Biology Section) of ARVO. In 2009, he was appointed an inaugural ARVO Fellow, Gold, of the 12,000-member organization. Dr. LaVail has been a member of the program committee and a Vice President of the International Society for Eye research. He also served on the Scientific Advisory Board of the Fou

ndation Fighting Blindness from 1973-2011. Dr. LaVail retired from the University of California on July 1, 2014, and now lives in a motor home with a permanent address somewhere in South Dakota.Catherine Bowes Rickman, Ph.D., is a tenured Associate Professor of Ophthalmology and of Cell Biology at

Duke University located in Durham, NC. Dr. Bowes Rickman leads a team of researchers focused on developing and using mouse models to understand the pathobiology of age-related macular degeneration (AMD) and on developing and testing therapeutic targets for AMD. Dr. Bowes Rickman earned her undergrad

uate degree from the University of California at Santa Barbara, majoring in Biochemistry/Molecular Biology and Aquatic Biology. She earned a Ph.D. from the University of California at Los Angeles and did a postdoctoral fellowship at the Jules Stein Eye Institute, California, where she focused on mou

se models of retinitis pigmentosa. Dr. Bowes Rickman has a long-standing interest in the molecular and cell biology and pathology of the retina. Amongst her seminal discoveries was the identification of the gene responsible for retinal degeneration in the rd mouse. She has applied her expertise in m

ouse genetics to develop models to study AMD. Currently, she is using several mouse models developed by her group that faithfully recapitulate many aspects of the human AMD phenotype to provide in vivo means to examine the pathogenic contribution of genetic, inflammatory and environmental factors to

AMD onset and progression. Recently, she successfully demonstrated a therapeutic rescue from dry AMD in one of these models. The last few years has been dedicated towards better understanding the impact of the complement system on the onset and progression of AMD using novel mouse models. Dr. Bowes

Rickman’s research program has been continually funded by the NIH since 1995 and she has also received support from Research to Prevent Blindness (RPB) Foundation, the Foundation Fighting Blindness, the Macular Degeneration program of the BrightFocus Foundation, Macula Vision Research Foundation, a

nd The Ruth and Milton Steinbach Fund. Dr. Bowes Rickman has received an RPB Career Development Award, an RPB William and Mary Greve Special Scholars Award and an Edward N. & Della L. Thome Memorial Foundation Award. She has published more than 50 original research and review articles and has edited

two books on inherited and environmentally induced retinal degenerations. She currently serves on the Scientific Advisory Boards of the Foundation Fighting Blindness (Owings Mills, Maryland), the Beckman Initiative for Macular Research (Irvine, California) and the Macular Degeneration program of th

e BrightFocus Foundation (Clarksburg, Maryland) and is a consultant for Aerie Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., GlaxoSmithKline, Inception Sciences and Pfizer.Joe G. Hollyfield, Ph.D., is Chairman of Ophthalmic Research and the Llura and Gordon Gund Professor of Ophthalmology R

esearch in the Cole Eye Institute at the Cleveland Clinic, Cleveland, Ohio. He received a Ph.D. from the University of Texas at Austin and did postdoctoral work at the Hubrecht Laboratory in Utrecht, The Netherlands. He has held faculty positions at Columbia University College of Physicians and Surg

eons in New York City and at Baylor College of Medicine in Houston, Texas. He was Director of the Retinitis Pigmentosa Research Center in The Cullen Eye Institute at Baylor from 1978 until his move to The Cleveland Clinic Foundation in 1995. He is currently Director of the Foundation Fighting Blindn

ess Research Center at the Cleveland Clinic and oversees activities of the Foundation Fighting Blindness Histopathology Center and Donor Eye Program. He has been an annual Visiting Professor in the Department of Ophthalmology at the University of Puerto Rico, Centro Medico, San Juan, Puerto Rico sin

ce 1974, where he and his wife, Mary E. Rayborn, teach the development and anatomy of the eye in the ＂Guillermo Pico Basic Science Course In Ophthalmology＂, given for ophthalmology residents in Puerto Rico and 18 other countries in Central and South America. Dr. Hollyfield has published over 200 pap

ers in the area of cell and developmental biology of the retina and retinal pigment epithelium in health and disease. He has edited 17 books, 16 on retinal degenerations and one on the structure of the eye. Dr. Hollyfield received the Marjorie W. Margolin Prize (1981, 1994), the Sam and Bertha Broch

stein Award (1985) and the Award of Merit in Retina Research (1998) from the Retina Research Foundation, Houston, Texas; the Olga Keith Weiss Distinguished Scholars’ Award (1981) and two Senior Scientific Investigator Awards (1988, 1994) from Research to Prevent Blindness, Inc., New York, New York;

an award from the Alcon Research Institute (1987), Fort Worth, Texas; the Distinguished Alumnus Award (1991) from Hendrix College, Conway, Arkansas; the Endre A. Balazs Prize (1994) from the International Society for Eye Research (ISER); the Proctor Medal (2009) from the Association for Research in

Vision and Ophthalmology (ARVO), and the 2009 Cless ＂Best of the Best＂ Award, given by the University of Illinois Eye and Ear Infirmary, Chicago, Illinois. He was an inaugural Gold Fellow of ARVO when this award was established in 2009. Since 1991 he has been Editor-in-Chief of the journal, Experime

ntal Eye Research published by Elsevier, Amsterdam, The Netherlands. Dr. Hollyfield has been active in ARVO since 1971, serving on the Program Committee (1976), as Trustee (Retinal Cell Biology, 1989-94), as President (1993-94) and as Immediate Past President (1994-95). He also served as President (

1988-91) and Secretary (1984-87) of the International Society of Eye Research. He is Chairman of the scientific review panel for the Macular Degeneration program of the BrightFocus Foundation (Clarksburg, Maryland), serves on the scientific advisory boards of the Foundation Fighting Blindness (Owing

s Mills, Maryland), the Helen Keller Eye Research Foundation (Birmingham, Alabama), the South Africa Retinitis Pigmentosa Foundation (Johannesburg, South Africa), is Co-Chairman of the Medical and Scientific Advisory Board of Retina International (Zurich, Switzerland), and is a member of the Board o

f Trustees of Hendrix College. He is now retired and living the good life in a penthouse apartment in Fort Myers, FL.Christian Grimm, Ph.D., is Professor for Experimental Ophthalmology at the University of Zurich, Switzerland. He received his Ph.D. degree at the Institute for General Microbiology at

the University of Berne in 1990. After an initial postdoc position in the field of snRNP maturation, Dr. Grimm conducted research at the University of Wisconsin in Madison, WI, where he studied nucleo-cytoplasmic transport of small RNAs. In 1997 Dr. Grimm moved back to Switzerland where he joined t

he Lab for Retinal Cell Biology in the Department of Ophthalmology at the University of Zurich. Dr. Grimm has led the Lab for Retinal Cell Biology since 2006 and was appointed Professor for Experimental Ophthalmology and joined the medical faculty in 2008. Dr. Grimm has published more than 120 origi

nal research and review articles, more than 100 in the field of retinal degeneration. His research focuses on molecular mechanisms of photoreceptor cell death, neuroprotection, and hypoxic signaling. Dr. Grimm has received the Alfred Vogt Award (2000), the Retinitis Pigmentosa Award of Pro Retina Ge

rmany (2003) and the Pfizer Research Award in Neuroscience (2004). He serves on the Editorial Boards of Current Eye Research, Experimental Eye Research, and Molecular Vision, and is Honorary Board member of Hypoxic Signaling. Dr. Grimm has received research grants from the Swiss National Science Fo

undation, the European Union, the University of Zurich and several private funding organizations. He serves on the Scientific Advisory Board of the Foundation Fighting Blindness, ProRetina Germany, and Retina Suisse, is director of the committee of the PhD program in integrative molecular medicine (

imMed) and of the Masters program of the medical faculty, and is Vice Chairman of the Center for Integrative Human Physiology, an interdisciplinary center of competence of the University of Zurich.

以監督式機器學習探討電子病歷中非結構化資料對早期預測中風後功能復原後果之價值

為了解決Geriatric functional的問題，作者宋昇峯 這樣論述：

中風是導致成人殘障的重要原因，中風功能復原後果的精準預測，能協助病人及家屬及早準備後續照顧事宜，衛生政策制定者也能依此預測結果適切規劃人力與資源，以投入中風病人的急性後期與中長期照護。目前的中風功能復原後果預測模型皆是以結構化資料建立，甚至最新使用數據驅動方式發展的機器學習預測模型依然是以結構化資料為主。相對的，照顧病人所製作的大量敘述式病歷文字紀錄，即非結構化資料，反而甚少被使用。因此，本研究的目的，即是使用監督式機器學習來探討非結構化臨床文字紀錄於急性缺血性中風後之初期預測功能復原後果之應用價值。在6176位2007年10月至2019年12月間因急性缺血性中風住院之病人中，共3847位病

人符合本研究之收案/排除條件。我們使用自然語言處理，萃取出住院初期之醫師紀錄及放射報告中之臨床文字紀錄，並且實驗了不同文字模型與機器學習演算法之組合，來建構中風功能復原後果的預測模型。實驗發現使用醫師紀錄時，操作特徵曲線下面積為0.782至0.805，而使用放射報告時，曲線下面積為0.718至0.730。使用醫師紀錄時，最好的組合為詞頻-倒文件頻加上羅吉斯迴歸，而使用放射報告時，最好之組合為基于轉換器的雙向編碼器表示技術加上支持向量機。這些基於純文字的機器學習預測模型並無法勝過傳統的風險模型，這些傳統模型的曲線下面積為0.811至0.841。然而，不管是以曲線下面積、重分類淨改善指標、或整合式

區辨改善指標來評估，臨床文字紀錄中的資訊的確可以增強傳統風險模型的預測效能。本研究之結論為，電子病歷中的非結構化文字經過自然語言處理後，不僅可以成為另類預測中風功能復原後果的工具，更可以增強傳統風險模型的預測效能。透過演算法來自動擷取並整合分析結構化與非結構化資料，將能提供醫師更好的決策支援。